FDA Chides Cipher Over Drug Ad's Superiority Claims
Canada-based Cipher Pharmaceuticals Inc. improperly advertised that its distinctive formulation of cholesterol drug fenofibrate makes the product more effective than versions sold by rival companies, according to a Thursday disciplinary letter...To view the full article, register now.
Already a subscriber? Click here to view full article